Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1995 1
1996 1
2011 1
2013 1
2014 1
2016 2
2017 1
2018 1
2019 1
2022 1
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

9 results

Results by year

Filters applied: . Clear all
Page 1
A randomized, controlled double-blind study comparing the efficacy and safety of dose-ranging voclosporin with placebo in achieving remission in patients with active lupus nephritis.
Rovin BH, Solomons N, Pendergraft WF 3rd, Dooley MA, Tumlin J, Romero-Diaz J, Lysenko L, Navarra SV, Huizinga RB; AURA-LV Study Group. Rovin BH, et al. Kidney Int. 2019 Jan;95(1):219-231. doi: 10.1016/j.kint.2018.08.025. Epub 2018 Nov 9. Kidney Int. 2019. PMID: 30420324 Free article. Clinical Trial.
Influence of ABCB1, CYP3A5 and CYP3A4 gene polymorphisms on prothrombin time and the residual equilibrium concentration of rivaroxaban in patients with non-valvular atrial fibrillation in real clinical practice.
Sychev DA, Sokolov AV, Reshetko OV, Fisenko VP, Sychev IN, Grishina EA, Bochkov PO, Shevchenko RV, Abdullaev SP, Denisenko NP, Ivashchenko DV, Sozaeva ZA, Kachanova AA. Sychev DA, et al. Among authors: reshetko ov. Pharmacogenet Genomics. 2022 Dec 1;32(9):301-307. doi: 10.1097/FPC.0000000000000483. Epub 2022 Oct 13. Pharmacogenet Genomics. 2022. PMID: 36256705
Filgotinib (GLPG0634/GS-6034), an oral selective JAK1 inhibitor, is effective as monotherapy in patients with active rheumatoid arthritis: results from a randomised, dose-finding study (DARWIN 2).
Kavanaugh A, Kremer J, Ponce L, Cseuz R, Reshetko OV, Stanislavchuk M, Greenwald M, Van der Aa A, Vanhoutte F, Tasset C, Harrison P. Kavanaugh A, et al. Among authors: reshetko ov. Ann Rheum Dis. 2017 Jun;76(6):1009-1019. doi: 10.1136/annrheumdis-2016-210105. Epub 2016 Dec 19. Ann Rheum Dis. 2017. PMID: 27993828 Free article. Clinical Trial.